A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications
Latest Information Update: 19 May 2026
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary) ; Cetuximab; Valproic acid
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 15 May 2026 Status changed from active, no longer recruiting to discontinued.
- 24 Apr 2026 Planned End Date changed from 31 Mar 2026 to 31 Oct 2026.
- 24 Apr 2026 Planned primary completion date changed from 31 Mar 2026 to 31 Oct 2026.